Swipe om te navigeren naar een ander artikel
The online version of this article (doi:10.1007/s11136-017-1547-z) contains supplementary material, which is available to authorized users.
The findings in this manuscript were presented in part at the American Society of Retina Specialists 33rd Annual Meeting in Vienna, Austria, July 10–14, 2015.
To determine changes in quality of life measures when choroidal neovascularization (CNV) developed in the second eye of patients with initially unilateral neovascular age-related macular degeneration (AMD).
We analyzed responses to the 39-item National Eye Institute Visual Function Questionnaire (NEI-VFQ), 36-item Short Form Health Survey (SF-36), and Hospital Anxiety and Depression Scale (HADS) at baseline, and prior to and following second eye CNV diagnosis in 92 participants enrolled in two Submacular Surgery Trials. Paired t-tests for sample sizes over 30 and Wilcoxon signed-rank tests for sample sizes <30 were performed to compare scores.
CNV development resulted in statistically and clinically significant changes in responses to 20 of 39 NEI-VFQ items, indicating visual function decline during a mean interval of 25 months. Little difference was noted between baseline scores and prior to CNV diagnosis, which averaged 8.9 months duration. Subscales demonstrated a statistically significant decline in general vision, near activities, distance activities, social functioning, role difficulties, dependency, and driving. There were minimal changes in the HADS and SF-36 scales.
CNV development in the second eye had a dramatic effect on visual functioning based on patient responses to the NEI-VFQ questionnaire. Our investigation is believed to be the first study using data collected prospectively to demonstrate vision-related quality of life changes that resulted from development of CNV in AMD patients.
Log in om toegang te krijgen
Met onderstaand(e) abonnement(en) heeft u direct toegang:
Supplementary material 1 (PDF 33 KB)11136_2017_1547_MOESM1_ESM.pdf
Supplementary material 2 (PDF 22 KB)11136_2017_1547_MOESM2_ESM.pdf
Supplementary material 3 (PDF 63 KB)11136_2017_1547_MOESM3_ESM.pdf
Supplementary material 4 (PDF 37 KB)11136_2017_1547_MOESM4_ESM.pdf
Supplementary material 5 (PDF 108 KB)11136_2017_1547_MOESM5_ESM.pdf
Klein, R., & Klein, B.E. (2013). The prevalence of age-related eye diseases and visual impairment in aging: current estimates. Investigative Ophthalmology & Visual Science, 54(14), ORSF5–ORSF13. CrossRef
Rein, D. B., Wittenborn, J. S., Zhang, X., Honeycutt, A. A., Lesesne, S. B., Saaddine, J., et al. (2009). Vision Health Cost-Effectiveness Study Group. Forecasting age-related macular degeneration through the year 2050: The potential impact of new treatments. Archives of Ophthalmology, 127(4), 533–540. CrossRefPubMed
Buckle, M., Lee, A., Mohamed, Q., Fletcher, E., Sallam, A., Healy, R., et al. (2015). Prevalence and incidence of blindness and other degrees of sight impairment in patients treated for neovascular age-related macular degeneration in a well-defined region of the United Kingdom. Eye (London), 29(3), 403–408. CrossRef
Complications of Age-Related Macular Degeneration Prevention Trial Research Group (2006). Laser treatment in patients with bilateral large drusen: The complications of age-related macular degeneration prevention trial. Ophthalmology, 113(11), 1974–1986. CrossRef
Ying, G. S., Huang, J., Maguire, M. G., Jaffe, G. J., Grunwald, J. E., Toth, C., Comparison of Age-Related Macular Degeneration Treatments Trials Research Group, et al. (2013). Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration. Ophthalmology, 120(1), 122–129. CrossRefPubMed
Schalnus, R., Meyer, C. H., Kuhli-Hattenbach, C., & Luchtenberg, M. (2010). Time between symptom onset and assessment in age related macular degeneration with subfoveal choroidal neovascularization. Ophthalmologica. Journal international d’ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 224(3), 176–182. CrossRefPubMed
Rauch, R., Weingessel, B., Maca, S. M., & Vécsei-Marlovits, P. V. (2012). Time to first treatment—the significance of early treatment of exudative age related macular degeneration. Retina (Philadelphia, Pa.), 32(7), 1260–1264. CrossRef
Submacular Surgery Trials (SST) Research Group (2007). Evaluation of minimum clinically meaningful changes in scores on the National Eye Institute Visual Function Questionnaire (NEI-VFQ). SST report number 19. Ophthalmic Epidemiology, 14(4), 205–215. CrossRef
Dong, L.M., Childs, A.L., Mangione, C.M., Bass, E.B., Bressler, N.M., Hawkins, B.S., Marsh, M.J., Miskala, P., Jaffee, H.A., McCaffrey, L.A., & Submacular Surgery Trials Research Group. (2004). Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4. American Journal of Ophthalmology. 138(1), 91–108. CrossRefPubMed
Submacular Surgery Trials (SST) Research Group (2004). Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: Quality-of-life findings. SST report no. 12. Ophthalmology, 111(11), 1981–1992. CrossRef
Submacular Surgery Trials (SST) Research Group (2004). Surgery for predominantly hemorrhagic choroidal neovascular lesions of age-related macular degeneration: Quality-of-life findings. SST report no. 14. Ophthalmology, 111(11), 2007–2014. CrossRef
The Alan Mason Chesney Medical Archives of the Johns Hopkins Medical Institutions. http://www.medicalarchives.jhmi.edu/. Accessed 19 Aug 2015.
Submacular Surgery Trials. (1998). Manual of Procedures. Spring-field, VA: National Technical Information Service. NTIS Publication PB98-16648.
Submacular Surgery Trials (SST) Research Group (2004). Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings. SST report no. 11. Ophthalmology, 111(11), 1967–1980. CrossRef
Mangione, C. M., Berry, S., Spritzer, K., Janz, N. K., Klein, R., Owsley, C., et al. (1998). Identifying the content area for the National Eye Institute Vision Function Questionnaire (NEI-VFQ): results from focus groups with visually impaired persons. Archives of Ophthalmology, 116(2), 227–233. CrossRefPubMed
Mangione, C.M. (2000). The National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25) Scoring Algorithm. Version August 2000. Available at: https://nei.nih.gov/sites/default/files/nei-pdfs/manual_cm2000.pdf Accessed August 19, 2015.
36-Item Short Form Survey (SF-36). http://www.rand.org/health/surveys_tools/mos/36-item-short-form.html. Accessed 20 Mar 2017.
Mangione, C.M., Lee, P.P., Gutierrez, P.R., Spritzer, K., Berry, S., Hays, R.D., National Eye Institute Visual Function Questionnaire Field Test Investigators. (2001). Development of the 25-item National Eye Institute Visual Function Questionnaire. Archives of Ophthalmology, 119(7), 1050–1058. CrossRefPubMed
Submacular Surgery Trials Research Group (2003). Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: Findings in patients with subfoveal choroidal neovascularization–SST Report No. 1. Archives of Ophthalmology, 121(4), 531–539. CrossRef
Likert, R. (1932). A Technique for the measurement of attitudes. Archives of Psychology, 140, 1–55.
Submacular Surgery Trials (SST) Research Group (2007). Incident choroidal neovascularization in fellow eyes of patients with unilateral subfoveal choroidal neovascularization secondary to age-related macular degeneration: SST report No. 20 from the Submacular Surgery Trials Research Group. Archives of Ophthalmology, 125(10), 1323–1330. CrossRef
Macular Photocoagulation Study Group (1993). Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Archives of Ophthalmology, 111(9), 1189–1199. CrossRef
Macular Photocoagulation Study Group (1997). Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Archives of Ophthalmology, 115(6), 741–747. CrossRef
- Visual function quality of life measure changes upon conversion to neovascular age-related macular degeneration in second eyes
Yannis M. Paulus
Joan L. Jefferys
Barbara S. Hawkins
Adrienne W. Scott
- Springer International Publishing